Find support groups, events and resources near you

Banner_Prostate Cancer News

FDA approves Pluvicto for progressive, PSMA-Positive metastatic CRPC

Doctor holding up a blue ribbon for prostate cancer awareness

The FDA has approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies.

To read the full story, click here.


Source: Kristi Rosa - OncLive